Miguel Regueiro
Miguel Regueiro is an expert in Gastroenterology at Cleveland Clinic (United States). As of October 2026, ScienceLeadR ranks Miguel Regueiro in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Miguel Regueiro has authored 776 publications, the most recent in 2026, and is an investigator in 12 clinical trials. SLR score: 2,951 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology - Public Health - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 776
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. PMID 42730438 — intestines, ustekinumab, opportunistic infections, fistula, safety, hospitalization, intestine, small, crohn disease, intestinal obstruction, cohort studies, propensity score, intestinal fistula, therapeutics, intestine, large, infections | Crohns Colitis 360 | 2026 | 0 |
| Risk of Extra-Intestinal Solid Organ Malignancy in Patients with Inflammatory Bowel Disease: A Propensity-Matched Cohort Study. PMID 42658757 — gastroenterology, neoplasms, cohort studies, thyroid gland, prostate, kidney, inflammatory bowel diseases, prostatic neoplasms | Digestion | 2026 | 0 |
| Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis. PMID 42611799 — glucagon-like peptide 1, glucagon-like peptide-1 receptor, inflammatory bowel diseases, body weight, weight loss | Dig Dis | 2026 | 0 |
| Reutilization of biologics for postoperative Crohn's disease recurrence prevention is effective. PMID 42560778 — confidence intervals, crohn disease, inflammatory bowel diseases, colitis, ulcerative | Inflamm Bowel Dis | 2026 | 0 |
| Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments. PMID 42520305 — ustekinumab, colitis, stroke, myocardial infarction, crohn disease, inflammatory bowel diseases, therapeutics, colitis, ulcerative, infections | Inflamm Bowel Dis | 2026 | 1 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
LeadR Networks
Main global connection map